Public Disclosure of Drug Manufacturer Payments to Patient Advocacy Groups
New legislation mandates pharmaceutical and device manufacturers to publicly disclose all payments made to patient advocacy organizations. This aims to increase transparency, helping citizens assess the independence of support provided by patient groups. Consequently, individuals can better understand potential financial ties within the healthcare sector.
Key points
Drug and device manufacturers must disclose payments to patient advocacy organizations.
Both direct and indirect payments, including those made through third parties, will be disclosed.
Information will be publicly available, increasing transparency in the funding of patient advocacy groups.
Introduced
Citizen Poll